Condition: Ras-mutated Metastatic Colorectal Cancer · mCRC · MSS Metastatic Colorectal Cancer · Sponsor: Oncolytics Biotech
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
This description comes directly from the study's public registry record.
Name: Reference Study ID Number: REO 033 · +1 (858) 247- 7829 · REO-033@oncolytics.ca
Always discuss trial participation with your own doctor first.
| Central Alabama Research | Homewood, Alabama, United States | Recruiting |
| Clinical Research Advisors (Beverly Hills) | Beverly Hills, California, United States | Not Yet Recruiting |
| Clinical Research Advisors (Encino) | Encino, California, United States | Not Yet Recruiting |
| Clinical Research Advisors (Korea Town) | Koreatown, California, United States | Not Yet Recruiting |
| Clinical Research Advisors (Downtown LA) | Los Angeles, California, United States | Not Yet Recruiting |
| Clinical Research Advisors (West Hollywood) | Los Angeles, California, United States | Not Yet Recruiting |
| Clinical Research Advisors (West Covina) | West Covina, California, United States | Not Yet Recruiting |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Not Yet Recruiting |
| Summit Health Cancer Center | Florham Park, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07446322